Oncometabolism

Publikováno v: International Journal of Molecular Sciences. 23(22)

Heart failure is associated with profound alterations in cardiac intermediary metabolism. One of the prevailing hypotheses is that metabolic remodeling leads to a mismatch between cardiac energy (ATP) production and demand, thereby impairing cardiac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od________83::8c2f37b5709daafe2feb080bc551d949
https://doi.org/10.3390/ijms232213902

Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy

Autor: Tim R Eijgenraam, Cornelis J. Boogerd, Xiaoke Yin, Manuel Mayr, Lukas E Schmidt, Herman H W Silljé, Eva van Rooij, Peter van der Meer, Nienke M Stege, Martin M Dokter, Rudolf A. de Boer, Vivian Oliveira Nunes Teixeira, Jolanda van der Velden, Konstantinos Theofilatos

Publikováno v: Circulation-Heart failure, 14(11):e008532. LIPPINCOTT WILLIAMS & WILKINS
Circulation. Heart failure, 14(11). Lippincott Williams and Wilkins Ltd.
Circulation. Heart failure, 14(11). Lippincott Williams and Wilkins
Circulation. Heart Failure
Eijgenraam, T R, Boogerd, C J, Stege, N M, Oliveira Nunes Teixeira, V, Dokter, M M, Schmidt, L E, Yin, X, Theofilatos, K, Mayr, M, van der Meer, P, van Rooij, E, van der Velden, J, Silljé, H H W & de Boer, R A 2021, ' Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy : Development of PLN-R14del-Related Cardiomyopathy ', Circulation. Heart failure, vol. 14, no. 11, pp. e008532 . https://doi.org/10.1161/CIRCHEARTFAILURE.121.008532

Supplemental Digital Content is available in the text.
Background: The p.(Arg14del) pathogenic variant (R14del) of the PLN (phospholamban) gene is a prevalent cause of cardiomyopathy with heart failure. The exact underlying pathophysiology is un

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f4ffc1ac9b8e1747e73da8397147370
https://doi.org/10.1161/circheartfailure.121.008532

Prognosis of patients eligible for dapagliflozin in acute heart failure

Autor: Nicolas Garin, Pauline Darbellay Farhoumand, Sebastian Carballo, Jacques Serratrice, Jérôme Stirnemann, David Carballo

Publikováno v: European journal of clinical investigation, Vol. 50, No 6 (2020) P. e13245

Background: Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, was shown in the DAPA-HF study to reduce the risk of worsening heart failure or death in symptomatic patients with left ejection fraction Materials and methods: Analysis of 815 pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11d67e9cdf0c024fc3282cd16ba7012b
https://doi.org/10.1111/eci.13245

Cardiac Obesity and Cardiac Cachexia: Is There a Pathophysiological Link?

Autor: Ivica Bošnjak, Diana Delić-Brkljačić, Kristina Selthofer-Relatić, Aleksandar Kibel

Publikováno v: Journal of Obesity
Journal of Obesity, Vol 2019 (2019)

Obesity is a risk factor for cardiometabolic and vascular diseases like arterial hypertension, diabetes mellitus type 2, dyslipidaemia, and atherosclerosis. A special role in obesity-related syndromes is played by cardiac visceral obesity, which incl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e344c4d53d5dc3638e9dcd04298be00
https://urn.nsk.hr/urn:nbn:hr:105:799773

Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry

Autor: Bossone, E., Arcopinto, M., Iacoviello, M., Triggiani, V., Cacciatore, F., Maiello, C., Limongelli, G., Masarone, D., Perticone, F., Sciacqua, A., Perrone-Filardi, P., Mancini, A., Volterrani, M., Vriz, O., Castello, R., Passantino, A., Campo, M., Modesti, P. A., de Giorgi, A., Monte, I., Puzzo, A., Ballotta, A., Caliendo, L., D’Assante, R., Marra, A. M., Salzano, A., Suzuki, T., Cittadini, A., Saccà, L., Monti, M. G., Napoli, R., Matarazzo, M., Stagnaro, F. M., Schiavo, A., Valente, P., Ferrara, F., Russo, V., Malinconico, M., Citro, R., Guastalamacchia, E., Leone, M., Amarelli, C., Mattucci, I., Calabrò, P., Calabrò, R., D’Andrea, A., Maddaloni, V., Pacileo, G., Scarafile, R., Belfiore, A., Cimellaro, A., Perrone Filardi, P., Casaretti, L., Paolillo, S., Gargiulo, P., Favuzzi, A. M. R., Di Segni, C., Bruno, C., Vergani, E., Massaro, R., Grimaldi, F., Frigo, A., Sorrentino, M. R., Malandrino, D., Manfredini, R., Fabbian, F., Ragusa, L., Carbone, L., Frigiola, A., Generali, T., Giacomazzi, F., de Vincentiis, C., Garofalo, P., Malizia, G., Milano, S., Misiano, G., Heaney, L. M., Bruzzese, D.

Publikováno v: Internal and emergency medicine. 13(5)

Recent evidence supports the concept that progression of chronic heart failure (CHF) depends upon an imbalance of catabolic forces over the anabolic drive. In this regard, multiple hormonal deficiency syndrome (MHDS) significantly has impacts upon CH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be7c0ffc4dba053ed8a57a6737222c88
https://pubmed.ncbi.nlm.nih.gov/29619769